Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chronic Pain After Thoracoscopic Pneumonectomy: A Multicenter, Randomized, Double-blind, Controlled Clinical Trial
Condition(s) studied
Investigational drug(s) / intervention(s)
Liposomal bupivacaine: Participants randomized to the intervention arm received 266 mg of liposomal bupivacaine for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline).
Bupivacaine Hydrochloride: Participants randomized to the intervention arm received 0.5% 100 mg of bupivacaine hydrochloride for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline)
Study summary
The goal of this clinical trial is to evaluate the efficacy and safety of liposomal Bupivacaine administered by paravertebral block for the treatment of acute and chronic pain after video-assisted thoracoscopic lobectomy.
Eligibility
Primary outcome measure(s)
- Area under the movement-evoked pain intensity-time curve — from 0-72 hours after the intervention
Area under the pain intensity-time curve in the movement (or coughing) state within 72h after the intervention. - The incidence of chronic postoperative pain — postoperative day (POD) 90
The incidence of chronic postoperative pain at 90 days
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| The Second Affiliated Hospital of Chongqing Medical University | Chongqing | Chongqing Municipality | Recruiting |
More The Second Affiliated Hospital of Chongqing Medical University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06569953 on ClinicalTrials.gov ↗ ← All trials in China